You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百奧泰(688177.SH)2021年度預盈6500萬-9500萬元 同比扭虧為盈
格隆匯 01-27 18:52

格隆匯1月27日丨百奧泰(688177.SH)公佈,公司預計2021年年度實現歸屬於母公司所有者的淨利潤與上年同期相比,將實現扭虧為盈,實現歸屬於母公司所有者的淨利潤為6500萬元到9500萬元。

預計歸屬於母公司所有者扣除非經常性損益後的淨利潤為2700萬元到4000萬元。

報吿期內業績變化主要是營業收入增加所致,與上年同期相比,營業收入增加6元到7億元,同比324.34%378.40%

1吿期內公司積極拓展更多的全球市場份額,與海內外多家企業進行商業合作。其中 Biogen International GmbH 簽署託珠單抗注射液授權許可與商業化協議,並且完成了協議中約定的階段性里程碑條件;同時,公司藥品普貝希®(貝伐珠單抗注射液)國家藥品監督管理批准的《藥品註冊證書》,達成百濟神州簽訂的授權許可與商業化協議中的階段性里程碑條件,授權許可收入大幅增加。

2期內公司積極拓展市場,業務規模逐步擴大,藥品格樂立®(阿達木單抗注射液)銷量逐步增加,預計銷售收入較上年同期增加1.1元到1.3同比增長60.15% 71.09%

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account